面向植物源外泌体的 for extracellular vesicles.
From research and IP to manufacturing, licensing and commercialization, BioThera runs every stage of its extracellular vesicle platform in Ottawa, Canada. BioThera is closing its current round in fall 2026. Investors and strategic partners are welcome to request information.
为什么选择EV生物制造？
细胞外囊泡蓄势重新定义下一代护肤。瓶颈不在于科学，而在于制造基础设施。这正是我们正在构建的。
A Defining EV Technology Platform
EVs are a powerful biological delivery system: characterized, standardized, and engineered for performance. BioThera is not building a single product. We are building the source-flexible EV platform that applications across the field require, starting with cosmetic applications and extending to therapeutic research.
The Infrastructure Gap
Scalable, standardized EV manufacturing is the critical missing piece preventing the EV field from maturing. We are building that infrastructure with documented quality control on every batch and the velocity of a startup.
Regulatory-Efficient Path
Cosmetic applications provide a regulatory-efficient path to validate the platform in the real world, generating operational data and proof points that carry across every application the platform supports.
您是合适的合作伙伴吗？
如希望了解平台、表征标准或授权模式，请在下方提交申请，我们将与您联系。
投资者数据室
包含详细资料，财务、知识产权概述、技术数据包和团队背景，的专用投资者门户在NDA下提供。请提交上方咨询以申请访问。
Forward-Looking NoticeThis page contains forward-looking statements based on current expectations. Actual results may differ materially. Nothing on this page constitutes an offer to sell or solicitation of an offer to buy securities. Any offering will be conducted under applicable private placement exemptions.
本页面仅供参考，不构成在任何司法管辖区出售任何证券的要约或购买任何证券的邀约。BioThera Solutions Inc.的任何证券发行将以私募方式进行，依据适用豁免条款，包括National Instrument 45-106（加拿大）下的认可投资者豁免、Rule 506 of Regulation D under the Securities Act of 1933（美国），以及其他司法管辖区的同等私募豁免条款。参与任何发行仅限于认可投资者、合格投资者或在其各自司法管辖区依据适用证券法豁免条款具备资格的其他人士。前瞻性声明反映当前预期，并受已知和未知的风险、不确定性及假设的影响，这些因素可能导致实际结果与预期存在重大差异。本通讯不构成投资建议。过去的业绩不代表未来的结果。